Pharm Inc Vertex

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

Molecular Insight Pharmaceuticals is a biopharmaceutical company based in Cambridge, MA, focused on developing innovative radiopharmaceuticals for the diagnosis and treatment of various diseases. With a team of dedicated researchers and scientists, the company is committed to advancing personalized medicine through cutting-edge molecular imaging technologies. Generated from their business information

Merrimack Pharmaceuticals is a privately held integrated biotechnology company. The company is dedicated to the discovery and development of therapies for the treatment of autoimmune disease and cancer. Its goal is to provide patients and physicians with some of the best possible treatments and support its pharmaceuticals with the tools to enable the prescription of the right drug for the right patient. The company is advancing a pipeline of clinical and early-stage biologics that represent patient-directed, targeted therapies. Its discovery and development efforts are founded on its proprietary Network Biology research engine. Its lead product, MM-093, is in clinical trials for the treatment of patients with rheumatoid arthritis and psoriasis. Merrimack Pharmaceuticals is based in Cambridge, Mass.